Institute for Molecular Medicine Finland (FIMM) is the Finnish node of the Nordic EMBL Partnership. FIMM's research focuses on human genomics and personalized medicine.
FIMM is an international research centre, with a main research focus on human genomics and personalized medicine. The centre integrates molecular medicine research, alongside a Technology Centre and Biobanking Infrastructures under one roof, thereby promoting translational research and the adoption of personalized medicine in healthcare.
FIMM researchers are involved in several Grand Challenge projects, such as the impact of genome information from the Finnish population in personalized health and medical interventions, development of individualized cancer medicine, and novel diagnostics via imaging of tissue and cells.The disease areas of interest for the 18 research groups cover cancer, cardiovascular diseases, diabetes, addictions, neurological and neuropsychiatric diseases and immunological diseases.
FIMM Technology Centre and Biobanking Infrastructures provide research services for local, national and international customers, including collaborations with companies.The infrastructures operated by FIMM are networked with European ESFRI infrastructures BBMRI, EATRIS, ELIXIR and EU-Openscreen
FIMM was founded in 2006 and is hosted by the University of Helsinki. The Hospital District of Helsinki and Uusimaa (HUS) and the National Institute for Health and Welfare (THL) were also involved in the establishment of the institute, and FIMM continues to maintain a close partnership with them. In early 2017, FIMM joined Helsinki University’s new life science research center, Helsinki Institute of Life Science (HiLIFE), as a scientifically and financially independent operational unit.